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The farnesoid X receptor (FXR) is involved in glucose and lipid metabolism regulation, which makes it an
attractive target for the metabolic syndrome, dyslipidemia, atherosclerosis, and type 2 diabetes. In order
to ﬁnd novel FXR agonists, a structure-based pharmacophore model collection was developed and theo-
retically evaluated against virtual databases including the ChEMBL database. The most suitable models
were used to screen the National Cancer Institute (NCI) database. Biological evaluation of virtual hits
led to the discovery of a novel FXR agonist with a piperazine scaffold (compound 19) that shows compa-
rable activity as the endogenous FXR agonist chenodeoxycholic acid (CDCA, compound 2).
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction receptor, or a homodimer.2 FXR, as a sensor for bile acids, isThe farnesoid X receptor (FXR, NR1H4), a ligand-dependent
transcription factor, is a member of the nuclear hormone receptor
superfamily comprising a highly conserved DNA-binding domain
in the N-terminal region and a moderately conserved ligand-bind-
ing domain in the C-terminal region.1 Two activation functions,
one ligand-independent (AF-1) and one ligand-dependent (AF-2),
are situated in the N-terminal and C-terminal regions, respec-
tively.1 Two cysteine-co-ordinated Zink ﬁngers located in the
DNA-binding domain are crucial for DNA binding and dimeriza-
tion.1 For the regulation of gene expression the nuclear receptor
FXR forms either a heterodimer with RXR, the 9-cis-retionic acidacid; AF, activation function;
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e’s Medium; EF, enrichment
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huster).
Y-NC-ND license.strongly involved in the regulation of target gene expression which
is crucial for bile acid biosynthesis and transport.3 Upon bile acid
binding, the nuclear receptor FXR undergoes conformational
changes and induces the expression of the small heterodimer part-
ner 1 (SHP-1), an atypical member of the nuclear receptor family
that lacks a DNA-binding domain.4 SHP-1 represses the expression
of CYP7A1, the rate-limiting enzyme in the conversion of choles-
terol into bile acids, by inhibiting the activity of the liver X receptor
(LXR) and the liver receptor homolog 1 (LRH-1; NR5A2).4–6
Moreover, the activated FXR regulates genes encoding the intesti-
nal bile acid-binding protein (IBABP) and the bile salt export pump
(BSEP).5,7,8 FXR, with its central function in the physiological main-
tenance of bile acid homeostasis, is expressed in liver, intestine,
kidney, and other cholesterol-rich tissues such as adrenal glands.9
Key bile acids in humans comprise the group of primary bile
acids with cholic acid (CA, 1), chenodeoxycholic acid (CDCA, 2),
as well as their glycine and taurine conjugates, and the group of
secondary bile acids with deoxycholic acid (DCA, 3) and lithocholic
acid (LCA, 4) (Chart 1).9
Several synthetic FXR ligands (Chart 1), that is, GW-4064 (5),
6-ethylchenodeoxycholic acid (6-ECDCA, 6), AGN-29 (7), and AGN-31
(8) have been generated for biomolecular investigations.10–12
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Chart 1. Examples for endogenous (1–4) and synthetic (5–10) FXR ligands.
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against the development of aortic plaques formation in murine
models characterized by a pro-atherogenic lipoprotein proﬁle
and accelerated atherosclerosis.13 In addition to these and other
synthetic compounds14–18 several natural products have been
found to act as potent FXR ligands and modulators, respectively.
These compounds include E- and Z-guggulsterone (9),19 stigmas-
terol, and its 3-acetate (10, Chart 1).20
Its regulative role in glucose and lipid metabolism in addition to
its complex architecture renders the nuclear receptor FXR an
attractive target for the discovery of novel bioactive compounds
with the ability to control endogenous pathways in close relation
to diseases, including the metabolic syndrome, dyslipidemia, ath-
erosclerosis, and type 2 diabetes.21,22 In order to identify novel
FXR agonists, a virtual screening workﬂow based on pharmaco-
phore modeling was established.
Structure- and ligand-based pharmacophore modeling and sub-
sequent virtual screening is a well-established workﬂow to iden-
tify new lead structures from compound libraries.23–25 The most
critical step hereby is the theoretically sound validation of the
screening models. Data sets for model validation, so-called test
sets, can be manually collected from literature or readily taken
from bioactivity databases. Until recently, several data sets con-
taining thousands of bioactive compounds with activity data from
literature, for example, the Derwent World Drug Index (WDI,
www.thomsonreuters.com), the WOMBAT database (www.sunset-
molecular.com), and the MDDR database (www.symyx.com) have
only been commercially available. With the start of the PubChem
project26 the tide shifted and a large amount of biological data be-
came available at no charge to the scientiﬁc community. Currently,
bioactivities for about 1000 targets (mostly HTS data) are included
in the PubChem BioAssay database. For these pharmaceutical tar-
gets, the PubChem contains a lot of useful information. A bigadvantage is the availability of large sets of conﬁrmed inactive
compounds which enable a thorough validation of virtual screen-
ing predictions. However, many targets are not contained in the
PubChem. Additionally, often only data from cell-based assays
(e.g., the overall effect on the growth rate of a tumor cell line is
measured) or qualitative data from high-throughput screening
assays are published. For many highly interesting targets, for
which hundreds of compounds are found in recent literature, only
a handful compounds are included in PubChem, for example, for
11-b-hydroxysteroid-dehydrogenase type 1, where just seven
compounds are found in the PubChem. For molecular modeling
studies, the knowledge about the molecular mode of action and
the potency of compounds is essential. Therefore, the exploitation
of the PubChem data for virtual screening studies is limited for
many pharmaceutical targets.
Recently, the ChEMBL database, which is the successor of the
Starlite database, was made publicly available.27 It is an open
access source for compounds with their associated biological data.
This project is funded by the Wellcome Trust, the EMBL member
states, the EU Innovative Medicines Initiative, and the EU
Framework 7 Program. The ChEMBL is an online database of
622,824 bioactive, drug-like, small molecules (version 02,
November 2009). The database contains 2D structures, calculated
properties such as molecular weight and Lipinski parameters,
and information on bioactivities (e.g., binding constants, inhibition
constants, and ADMET data). These data are extracted from the pri-
mary literature including some of the most important medicinal
chemistry journals (e.g., J Med Chem, Bioorg Med Chem, Bioorg
Med Chem Lett) and other leading publications (e.g., Nature and
Science). From this point of view, the ChEMBL very much
resembles the WOMBAT database, but contains a larger amount
of validated information. Recently, PubChem now also contains
the ChEMBL bioactivity data sets, which makes it convenient to
7170 D. Schuster et al. / Bioorg. Med. Chem. 19 (2011) 7168–7180search for activity data using just one search portal. In this study,
the ChEMBL was analyzed for its composition and separated in tar-
get-speciﬁc subsets. Additionally, it was used besides other data
sets to validate the generated FXR pharmacophore models.
No 3D pharmacophore-based virtual screening study on FXR
has been published before. In this study, we systematically devel-
oped a structure-based pharmacophore model collection, theoret-
ically validated it on active FXR ligands and decoys from the
ChEMBL, and used it to virtually screen the National Cancer Insti-
tute (NCI) database.28 Selected virtual hits from the NCI were bio-
logically evaluated, which led to the identiﬁcation of a novel
scaffold that could serve as lead structure for FXR agonist design.
2. Results and discussion
2.1. Data sets
2.1.1. ChEMBL database
The ChEMBL database is readily available as downloadable
structure-data (SD) ﬁle (www.ebi.ac.uk/chembldb/). However, this
ﬁle does not include bioactivity information. Accordingly, structure
and bioactivity data were merged as described in the experimental
section. The data merging and ﬁltering process resulted in a data-
base with 302,924 (version 02) unique entries, all with annotated
biological activity. For the majority of compounds, one or two
activities on biological targets are included. However, there is also
a considerable number of compounds with more than ten indi-
cated bioactivities (Fig. 1).
The ChEMBL reports data on 3,485 differently annotated phar-
macological targets. However, some targets are present more than
once, with similar names; for example, 11-b-hydroxysteroid-dehy-
drogenase-1/11-beta-hydroxysteroid-dehydrogenase type 1, al-
pha-L-fucosidase-1/alpha-L-fucosidase-I, or carbonic-anhydrase-1/
carbonic-anhydrase-I, to name a few.
2.1.2. FXR-actives
The set of active FXR ligands, that will further be referred to as
‘FXR-actives’ was extracted from the ChEMBL database using the
workﬂow described in the experimental section. In the ChEMBL,
FXR ligands are annotated as ‘bile acid receptor FXR’ ligands. Out
of the initially 326 FXR ligands from ChEMBL, only unique ligands
that were reported as active (EC50 <100 lM) were kept. As this was
the pilot study using the ChEMBL database, nothing was known
about the error rate regarding the reported molecular structures
and bioactivities. Therefore, the 2D structures and the biological
data were manually compared to the values from the original liter-
ature (Supplementary data Refs. 1–16). Remarkably, all remaining
224 2D structures and reported biological activities in the FXR-ac-
tives ChEMBL subset perfectly matched the data reported in liter-Figure 1. Number of targets reported per ChEMBL compound.ature. Where more than one FXR activity value was reported for
a ligand, the least active one was found in the ChEMBL. The ﬁnal
3D multiconformational FXR-actives data set comprised 221
compounds.
2.1.3. FXR-decoys
The FXR-decoy set was extracted from the ChEMBL database.
Compounds with similar physicochemical properties like the
FXR-actives (molecular weight, c logP, number of hydrogen bond
donors, number of hydrogen bond acceptors, and number of aro-
matic rings) were selected. The ﬁnal FXR-decoy database com-
prised 5598 entries.
2.1.4. DrugBank
The DrugBank is a publicly available database that links drug
information with target data.29 Currently, the DrugBank contains
about 4,800 small molecule entries including over 1,350 FDA-ap-
proved small molecules and over 3,240 experimental drugs, be-
sides smaller compound groups.
2.1.5. Virtual DB
Previously, we have generated a virtual database using the pro-
gram ilib diverse (www.inteligand.com) that contains 12,775 pre-
sumably inactive decoy molecules.30 This data set – the so-called
Virtual DB – has been designed to include nonreactive, drug-like
compounds and is frequently used in our group to assess a model’s
ability to discard inactive compounds in a database screen.
2.1.6. NCI database
The compound database of the NCI is part of the Developmental
Therapeutic Program. As a part of the whole concept, it offers small
molecule compounds to research institutions free of charge. The
database is available as SD ﬁle which can be downloaded and used
for virtual screening experiments.
2.2. Analysis of the ChEMBL database and comparison with
other databases
In order to evaluate the suitability of the ChEMBL database as
benchmarking data set for virtual screening aiming at lead discov-
ery, the physicochemical property distribution of the ChEMBL
compounds was calculated, analyzed, and compared to marketed
and investigational drugs from the DrugBank. In order to addition-
ally get insights into the physicochemical property distribution our
Virtual DB, that we frequently use as decoy set for model valida-
tion, we also compared this data sets with the ChEMBL and the
DrugBank compounds.
The generated ChEMBL database contains 302,924 unique
chemical structures. About two third – 196,381 compounds –
match Lipinski’s Rule of Five criteria for drug-likeness.31 With re-
spect to the deﬁnition of Irwin et al.32 56,086 compounds are
lead-like possessing a molecular weight between 150 and 350, a
maximum number of hydrogen bond (H-bond) donors of 3, at most
6 H-bond acceptors, and a c logP lower than 4. Finally, 10,085
structures are fragment-like with a molecular weight less than
250, a number of H-bond donors less than 3, a number of H-bond
acceptors less than 6, a c logP between 2 and 3, and a number of
rotatable bonds less than 3.33 A detailed distribution of molecular
properties and the number of violations of Lipinski’s Rule of Five
are shown in Figure 2.
When comparing the DrugBank, the ChEMBL, and the Virtual
DB, the numbers of H-bond acceptors and donors, the c logP values,
the number of rotatable bonds, and the number of Lipinski Rule of
Five violations are similarly distributed in the respective databases.
Remarkably, the DrugBank contains the largest fraction of very ri-
gid compounds bearing no or only 1 and 2 rotatable bonds. The
Figure 2. Molecular property distribution of the ChEMBL database compounds compared with the DrugBank and Virtual DB.
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distribution, where the ChEMBL includes more compounds with a
high molecular weight. The DrugBank includes the highest fraction
of small compounds among the three databases. The Virtual DB
was optimized in molecular property distribution during database
generation following guidelines for druglikeness30 and therefore it
is not surprising that it follows a smooth Gaussian-like curve in
molecular weight distribution.
2.3. Analysis of FXR ligand binding modes
FXR is known to accommodate a ﬂexible ligand binding domain,
where ligand binding changes the position of the AF-12 helix and
thus the recruitment of co-activator or -repressor proteins. For
pharmacophore model generation, a systematic understanding of
ligand binding and the elucidation of essential amino acids partici-
pating in the process is crucial. Therefore, the published X-ray crys-
tal structures of FXR-ligand complexes available at the time of this
study were extracted from the Protein Data Bank34 (PDB, entries
1osh,35 3bej,36 3dct,37 3dcu,37 3ﬂi,38 3fxv,39 3gd2,40 3hc5,41 and
3hc6;41 Fig. 3) and analyzed for their protein–ligand interactions
(Table 1).
The nine PDB entries represent four structural classes: y-shaped
hydrophobic compounds (1osh), tricyclic heteroaromatic com-
pounds (3ﬂi), steroids (3bej), and derivatives of compound 5
(3dcu = compound 5, derivatives: 3dct, 3gd2, 3fxv, 3hc5, and
3hc6). The latter share very similar bindingmodes (Figs. 3 and 4, Ta-
ble 1); thus, these structures were represented by a single model,
while for the other PDB entries, one model was created for each
structure.
For 1osh and 3ﬂi, conformational changes of the binding pocket
and the observation of different interaction patterns between the
ligand and the protein were observed. In addition, a 15 amino acid
long ﬂexible loop between helices 1 and 3 is completely distorted
and therefore missing in the X-ray structure 1osh. Accordingly,
1osh and 3ﬂi have to be treated separately for model building.
The steroidal ligand from 3bej ﬁts well into the compound 5-
formed binding site. However, the location of the acidic function
differs so that it establishes other interactions with the protein.
In addition, 5-based ligands occupy a larger part of the binding site
and thus form interactions that are not observed for 3bej. There-
fore, 3bej was also subject of separate model generation.2.4. Pharmacophore model generation and validation
Pharmacophore models based on the PDB entries 1osh, 3bej,
3ﬂi, and 3dct, respectively, were generated using LigandScout soft-
ware (www.inteligand.com). From each entry, several models were
built that differed in the number and composition of chemical fea-
tures, so that distinctive binding modes were reﬂected by the mod-
els. The resulting models were exported into DiscoveryStudio for
optimization and virtual screening. For each model, one version
containing a shape restriction was generated. All pharmacophore
models were validated by calculating enrichment factors (EFs)
using the FXR-actives data set and the complete ChEMBL as decoy
set (best models see Table 2). For comparison, EFs using the FXR-
decoys, the Virtual DB, and the DrugBank as decoy sets were calcu-
lated as well.
2.5. Description of the generated pharmacophore models
2.5.1. 1osh-1(-s) and 1osh-2-(s)
The ﬁrst pharmacophore model derived from 1osh (1osh-1)
consisted of ﬁve hydrophobic features, one H-bond acceptor with
His294, and 27 exclusion volume spheres ( Fig. 5A). Due to the
missing loop between helices 1 and 3, no exclusion volume spheres
could be placed on this part of the binding site. However, as this
region is considered as highly ﬂexible, it could adapt to the size
of a ligand and thereby not be a strict sterical restriction for ligand
binding. The model mainly recognized fexaramine analogs from
the FXR-actives data set. However, also one steroidal hit with an
EC50 of 11.6 lM returned from the FXR-actives set. According to lit-
erature data, hydrophobic contacts are established between the
methyl ester group and the FXR binding pocket. Thus, a model con-
taining this additional feature was created. However, this model
was very restrictive. In order to provide a less restrictive model,
the hydrophobic feature on the dimethylamine group was deleted.
The resulting model (1osh-2) performed well in the theoretical val-
idation. Although the 1osh-1 and 1osh-2 models are very similar to
each other, their FXR-actives hitlists differed from each other. Eight
out of 51 FXR-actives hits from the 1osh-1 model were not recog-
nized by 1osh-2. Vice versa, 26 out of 69 FXR-actives hits from the
1osh-2 model did not ﬁt into the 1osh-1 model. Thus, both models
were kept in the ﬁnal model collection. The comparison of the
shape-containing models revealed similar results (eight out of 34
Figure 3. FXR agonists that have been co-crystallized with human FXR and served for binding mode analysis and training compounds for structure-based pharmacophore
model generation. The corresponding PDB code is given for each compound and chemical interactions are shown in 2D.
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based FXR-actives screenings, respectively). The shape-containing
models (1osh-1-s and 1osh-2-s) outperformed the initial models
with up to 18-fold higher EFs (Table 2).
2.5.2. 3bej-1(-s) and 3bej-2(-s)
The initial pharmacophore model based on the PDB entry 3bej
(3bej-1) included three hydrophobic features, two H-bond accep-
tors anchoring the ligand with His294 and Thr288, a negatively
ionizable feature representing the interaction with Arg331, and25 exclusion volume spheres (Fig. 5B). In the database search of
the FXR-actives set, the 3bej-1 only returned compound 5-related
hits. This reﬂects the binding similarities between compounds 5
and 13, although they belong to completely different chemical
scaffolds. Because 3bej-1 was very restrictive, a model variation
was created that only contained the chemical features on the
steroidal core and the neighboring atoms. The hydrophobic feature
and the H-bond acceptor on the p-hydroxyphenyl ring were
deleted resulting in model 3bej-2. This reduced model correctly
identiﬁed FXR ligands from diverse chemical scaffolds including
Table 1
Protein–ligand interactions observed in FXR–agonist complexes from the PDB. Hydrophobic interactions are indicated as H, H-bond acceptors/donors as HBA/D, and negatively
ionizable groups as NI
Amino acid 1osh* 3ﬂi* 3bej 3dct 3dcu 3fxv* 3gd2 3hc5 3hc6
Met265 H H HBA, H HBA, H H HBA, H H H
Ile269 H
Thr270 HBA, H H H H H H
Ile273 H H
Phe284 H H H H H H H H H
Leu287 H H H H H H H H H
Thr288 HBA/D, H H H H H H H
Met290 H H H H H H H H H
Ala291 H H H H H H H H H
His294 HBA HBA
Val325 H H H H H
Met328 H H H H H H H H H
Phe329 H H H H H H H H
Arg331 H NI, HBA NI, HBA NI, HBA, H NI, HBA, H NI, HBA, H NI, HBA, H NI, HBA, H
Phe333 HBA
Ile335 H H H H H H H H H
Phe336 H H
Leu340 H
Ser342 H
Leu348 H H H H H H H
Leu352 H H H H H
Ile352 H H H H
Ile357 H H H H H H H H
Tyr361 H
Ile362 H
Met365 H H H H H H H H
Phe366 H
Tyr369 HBA, H
His447 HBA
Met450 H H H H H
Leu451 H
Trp454 H H H H H H
Phe461 H H H
Trp469 H H H H H H
* The amino acid numbering of 1osh, 3ﬂi, and 3fxv differ from the other structures by +4. For better comparison, the amino acid numbering was synchronized in this table
(e.g., Met269 in 1osh is Met265 in this table).
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ished EF. The addition of a shape to the 3bej-2 model (3bej-2-s) re-
stricted the virtual hits to those compounds that also fulﬁlled the
geometric requirements for FXR binding, which led to a consider-
able EF improvement (Table 2).
2.5.3. 3dct(-s)
The model built from the PDB entry 3dct was not only based on
ligand binding information from this structure, it represented the
observed binding interactions of all compound 5 derivatives that
have been co-crystallized with FXR. The model 3dct consisted of
ﬁve hydrophobic features, one H-bond acceptor with His294, one
negatively ionizable group, and 29 exclusion volume spheres (
Fig. 5C). From the FXR-actives set, the model retrieved only deriv-
atives of compound 5. Due to the strong focus on a relatively high
MW compound class and the high number of chemical features,
the model was very restrictive. The shape-containing version of
3dct (3dct-s) retrieved the highest EFs in this study (Table 2).
2.5.4. 3ﬂi(-s)
Based on the PDB entry 3ﬂi, which shows a distinct FXR ligand
binding domain conformation compared with the other entries, a
relatively unrestrictive 3D pharmacophore model was created.
The positively charged side chain of Arg331 points away from
the ligand, therefore allowing only hydrophobic interactions.
His294 is not engaged in direct protein–ligand interactions. As a
particularity of this structure, the H-bond with Tyr369 was kept
for the model, along with four hydrophobic features and 28 exclu-
sion volume spheres (Fig. 5D). Due to the comparably few chemicalfeatures that formed this model, many hits were retrieved from the
FXR-actives set including compound 5-like compounds, steroids,
and derivatives of compound 13. However, 3ﬂi also returned the
largest number of inactive decoys from the Virtual DB which led
to a comparably low EF. (Table 2).
2.6. Theoretical Evaluation of the FXR model collection using
the ChEMBL, FXR decoys, DrugBank, and Virtual DB
In order to assess the overall performance of the model collec-
tion, the individual hit lists from the FXR-actives, FXR-decoys,
ChEMBL, DrugBank, and Virtual DB were merged for each model,
respectively, and cleared from duplicate entries. In the ﬁnal ﬁle,
all hits from a database, for example, all FXR-actives that were re-
trieved by any of our models, were present once. The model collec-
tion was able to retrieve 194 out of 221 (87.8%) FXR-actives. EFs for
the parallel screening of the databases were 5.5 or lower (Table 2).
The impact of low quality models was assessed by discarding the
3ﬂi(-s) models and re-evaluating the respective EFs. Still, 162
FXR-actives (73.3%) from different chemical scaffolds were cor-
rectly recognized. The rates of false positive hits decreased over
50% thereby improving EFs for all four databases (Table 2). By addi-
tionally eliminating the unrestrictive model 2bej-2, still 122
(55.2%) of FXR-actives were retained while raising the EF for the
ChEMBL up to 11.5. Obviously, the inclusion of models with low
restrictivity and low EF into a model collection can considerably
impair the predictive power of the entire system. Accordingly,
the advantage of using multiple restrictive pharmacophore models
representing different binding modes for one target compared to
Figure 4. Comparison of FXR ligand binding modes and conformational changes of the binding pocket. (A) Binding modes of 5 (3dct) and its derivatives 14 and 16–18.
Hydrophobic areas on the ligands are indicated in yellow, the charged interaction with Arg331 is depicted as red star, and H-bonds with Met265 and Arg331 are highlighted
by red arrows. (B) Comparison of binding modes for 11 (black) and 15 using the 3fxv binding pocket. Compound 11 sterically clashes with the binding site in the 3fxv
conformation. (C) Compound 13 ﬁtted into the 3dct binding pocket, sharing a large part of it. The acidic functions differ in location and observed interactions. (D) Compound
12 ﬁtted into the 3fxv binding pocket. The diﬂuorophenyl moiety of 12 sterically clashes with the binding pocket conformation from 1fxv.
Table 2
Performance of the generated pharmacophore models in screening the FXR-actives dataset and the validation DBs ChEMBL, DrugBank, and the Virtual DB. The model quality was
assessed by EF calculations
Model Hits FXR-
actives
(n = 221)
Hits ChEMBL
(n = 304,052 w/o FXR-
actives)
EF ChEMBL/
model rank
Hits
DrugBank
(n = 4,722)
EF
DrugBank/
model rank
Hits Virtual
DB
(n = 12,775)
EF Virtual
DB/model
rank
Hits FXR
decoys
(n = 5,598)
EF FXR
decoys/
model rank
1osh-1 51 10,139 6.9/9 73 9.2/9 99 19.2/8 526 2.3/10
1osh-1-s 34 350 121.9/3 2 21.1/4 5 51.3/6 17 17.6/4
1osh-2 69 2688 34.5/6 13 18.8/5 32 40.2/7 159 8.0/6
1osh-2-s 44 114 383.4/2 2 21.4/3 2 56.2/5 7 22.7/2
3bej-1 7 777 12.3/8 5 13.0/8 0 58.8/1 27 5.4/8
3bej-1-s 7 648 14.7/7 4 14.2/6 0 58.8/1 24 5.9/7
3bej-2 119 33280 4.9/10 316 6.1/10 429 12.8/9 982 2.8/9
3bej-2-s 100 1552 83.3/5 66 13.5/7 415 11.4/10 57 16.8/5
3dct 57 734 99.2/4 2 21.6/2 2 56.8/4 23 18.8/3
3dct-s 43 12 1076.4/1 0 22.4/1 0 58.8/1 1 25.7/1
3ﬂi 143 61,788 3.2/12 427 5.6/12 1572 4.9/11 2473 1.4/11
3ﬂi-s 135 55,965 3.3/11 381 5.9/11 1542 4.7/12 2396 1.4/12
All 194 82,006 3.2 654 5.1 1895 5.5 2927 1.6
All without
3ﬂi-
models
162 40,979 5.4 374 6.8 531 13.7 1389 2.8
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way to avoid a high number of false positive hits.
As can be seen from the EFs calculated for the four different dat-
abases (Table 2), EFs cannot be directly compared in order to get an
idea how predictive a model is. The reason lies in EF calculation,
which is based on the distribution between active and (putative)
inactive molecules within the validation database. The maximum
EF, which is reached when only active and no inactive compound
are returned from database screening, is for the ChEMBL 1376.8,
for the FXR-decoys 26.33, for the DrugBank 22.4, and for the VirtualDB 58.8. Therefore, a model ranking based on EFs was performed
(Table 2). For most models, the obtained rank was equal or similar
(±1) in the compared rankings. The best-ranked model was 3dct-s
in all three rankings, the lowest ranks were assigned to the 3ﬂi(-s)
models.
EF differences were most pronounced in the ChEMBL, which al-
lowed for a clearer ranking of models. For example, 1osh-2-s and
3dct show very close EFs in the DrugBank (21.4 vs 21.6) and in
the Virtual DB (56.2 vs 56.8), respectively. Only the ChEMBL-based
EF calculation revealed a considerable better performance of the
Figure 5. Pharmacophore models for FXR ligands. Chemical features are color-coded: yellow – hydrophobic, red arrow – H-bond acceptor. (A) Model derived from the
binding of 11 to FXR. His294 is shown in ball-and-stick style. (B) Compound 13-based model. His294 and Arg331 are shown in ball-and-stick-style. (C) Compound 5-scaffold
model. (D) Compound 12-based model. Tyr369, the H-bonding partner, lies behind the molecule in this perspective; therefore, the H-bond acceptor is not visible. For showing
how much the FXR binding pocket changes upon ligand binding compared to 5, His294 and Arg331 are also depicted in ball-and-stick-style.
D. Schuster et al. / Bioorg. Med. Chem. 19 (2011) 7168–7180 71751osh-2-s model (EF 383.4 vs 99.2 for 3dct). Another big advantage
of the ChEMBL is that all compounds include bioactivity informa-
tion. Thus, the user is able to study retrieved hit lists in more detail
and evaluate whether false positive hits belong to related targets
and may therefore be active.
The most challenging data set for discriminating FXR-active
from putatively inactive molecules was the FXR-decoy database.
In comparison to the DrugBank-based validation (which has a sim-
ilar maximum EF as the FXR-decoys), most EFs were lower when
using the FXR-decoy set. However, some models were still able
to considerably enrich active compounds in the FXR-active versus
FXR-decoy validation experiments (Table 2). EFs of around 17 and
up were achieved with the models 1osh-1-s, 1osh-2-s, 3bej-2-s,
and 3dct(-s), pointing towards a highly favorable impact of the
shape restriction to the models performance.
2.7. Model collection evaluation with FXR agonists from recent
literature
The ChEMBL dataset in its used version (02) did not contain the
most recent ligands from literature. For a theoretical model evalu-
ation that was not relied on the ChEMBL database, FXR agonists
were collected from the most recent literature, starting December
2009. Only two papers have been published at the time of this
study: Iguchi et al.42 reported on steroidal, bile acid-related FXR
agonists, while Lundquist et al.43 presented tetrahydroazepinoin-
dole derivatives (Supplementary data, Chart S-1). The 15 most
active compounds from both papers were prepared for virtual
screening and submitted to pharmacophoric proﬁling by the FXR
pharmacophore model collection. All but one out of 15 compounds
were correctly retrieved by at least one of the models. These resultsfurther conﬁrmed the accuracy of the pharmacophore model
collection.
2.8. Selection of virtual hits for biological testing
In order to experimentally verify the quality of high-quality
models, virtual hits were selected for biological testing. The
3dct(-s) models were not able to ﬁnd compounds classically con-
sidered as drug-like according to their physicochemical properties
(compare Fig. 2). The reason for this lies in the high number of
chemical features forming the model, making it very specialized
for compound 5-like molecules. Although it can’t be ruled out that
the 3dct(-s) models ﬁnd interesting hits in compound databases,
that was not the case for the NCI database. The 3ﬂi(s) models
and 3bej-2 showed the lowest EFs for all validation databases (Ta-
ble 2) and were therefore also discarded for further virtual screen-
ing studies. Of the remaining models, those with the best EFs
(compare Table 2), that is, the shape-containing models, and a
high restrictivity were employed to select virtual hits from the
NCI database. 1osh-1-s returned 126 hits, 1osh-2-s 59 hits, and
3bej-1-s 32 hits. Among the 217 total hits, 170 were very ﬂexible
with more than 10 rotatable bonds. These compounds were ex-
cluded from further investigations. The remaining 47 hits were
visually inspected for their predicted binding pose. Based on these
results and the current compound availability at the NCI, eight
structurally diverse compounds were submitted to in vitro evalu-
ation of their agonistic effect on human FXR. Four compounds
were taken from the 1osh-1-s hitlist, the other four from the
3bej-1-s hitlist (Chart 2). All compounds that were selected to
validate hits from the 1osh-2-s hitlist were not available at the
time of our request.
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Chart 2. Virtual hits from the models 1osh-1-s and 3bej-1-s that were tested for biological activity in the FXR transactivation assay.
Figure 6. Reporter gene assay for FXR activation. Application of increasing
concentrations (10 nM–100 lM) of the virtual hits 19 (A) and 20 (B), respectively,
leads to dose dependent signal increase. FXR activity is expressed as fold difference
of relative luciferase units (RLU) represented by mean values ± SEM resulting from
triplicate determinations of three independent experiments (⁄P <0.05, ⁄⁄P <0.01).
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Biological evaluation of the substances with respect to their
ability to activate FXR was performed in HEK293 cells transiently
transfected with elements of the FXR reporter assay system com-
prising the ECRE-Luc reporter plasmid containing quintuple
RXR:FXR binding site and the respective expression plasmids for
full length murine FXR and RXRa. The cells were treated with
increasing concentrations (0–100 lM) of the speciﬁc FXR ligand
2, or with the selected virtual hits 19–26, respectively. A dose–
dependent FXR-agonism was observed for compounds 19 and 20,
whereas 21–26 were inactive. Activation of FXR by the respective
ligand reached statistical signiﬁcance between 1 and 10 lM, at
concentration of 100 lM the system was saturated. The estimated
EC50 values of the novel agonists were with 3.15 lM for 19 and
6.17 lM for 20 more active than substance 2 (16.8 lM) as shown
in Figure 6. Compound 19 represents a so-far novel chemical scaf-
fold for FXR agonists (see ‘novelty assessment of compound 19’ in
Section 4). Therefore, it can serve as a lead structure for developing
a new series of more potent FXR agonists.
In order to obtain an independent evidence of the ability of 19
and 20 to activate FXR, we tested their effects on the expression
of a gene known to be downstream of FXR. CYP7A1 expression is
down-regulated by FXR via a well-characterized molecular mecha-
nism involving SHP and LRH-1, and is widely used to monitor
activity of endogenously expressed FXR.44 In full agreement with
our promoter–reporter data, the two compounds signiﬁcantly
decreased levels of CYP7A1 mRNA; the degree of inhibition was
similar to that induced by the classical FXR agonist 2 (Fig. 7).
In addition, it was investigated if there have already been
reports on the biological properties of 19. In the literature, this
compound has never been reported before. The enhanced NCI data-
base browser (129.43.27.140/ncidb2/), where biological data from
in-house screens by the NCI are reported, no experimental results
were given for compound 19. Additionally, the structural topologyof 19was compared to known bioactive molecules from the WOM-
BAT and MDDR databases using the publicly available similarity
search portal at sea.docking.org.45 Finally, the 1-(4-methylpipera-
zin-1-yl)-3-phenoxypropan-2-ol core structure was used as sub-
structure search query in the online version of the ChEMBL DB
(version 09). All 371 compounds that returned from this search
Figure 7. Expression of CYP7A1mRNA. HepG2 cells treated with 19 and 20 (50 lM)
for 6 h in DMEM containing 10% FCS; data expressed as fold of control cells treated
with medium/0.1% DMSO (⁄P <0.05, ⁄⁄P <0.01, ⁄⁄⁄P <0.001).
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Also in these experiments, the compound or related molecules
from this scaffold were not associated with FXR or any other nucle-
ar receptor, underscoring the novelty of this chemical scaffold for
FXR agonist design.
2.10. Mapping of compound 19 into the FXR binding pocket
The mapping conformation of compound 19 was ﬁtted and
energetically minimized into the FXR binding site. The resulting
binding pose suggested a similar interaction pattern compared to
the co-crystallized ligand compound 11, however, additional
hydrogen bonds and fewer hydrophobic interactions were pre-
dicted (Fig. 8). Compound 19 was observed to be anchored within
the receptor by additional hydrogen bonds to Ser332 and Tyr369
compared to the binding mode of compound 11. Although the
piperazine ethylene moiety of 19 was mapped into a hydrophobic
feature in the pharmacophore-based search, no such interactions
could be observed in the minimized binding pose prediction. In
fact, piperazine rather increases the hydrophilicity of a compound
due to its basic character. The piperazine moiety can therefore beFigure 8. Mapping of compound 19 (black) into the FXR ligand binding site. In comparis
bonds (arrows) between the hydroxy group and Ser332/Tyr369. The hydrogen bond
respectively. Hydrogen bond-forming amino acids are depicted in ball-and-stick style. T
compounds 11 and 19. The piperazine moiety was not observed to form direct interac
spacer.seen as a spacer linking two hydrophobic parts of the molecule,
which enhances the compound’s solubility.
The generated pharmacophore models have been successfully
applied to screen our in-house Chinese Herbal Medicine (CHM)
database46 comprising 10,216 compounds, which are related to
natural products used in traditional Chinese medicine. This in silico
approach led to the identiﬁcation of lanostane-type triterpenes
from the mushroom Ganoderma lucidum as active FXR ligands. A
complete description of this work is provided in part II of this
study.47
3. Conclusions
The present work shows how a model collection for FXR can be
assembled and thoroughly theoretically validated. In comparison
to smaller DBs, the ChEMBL returns more distinct EFs from valida-
tion screenings. The developed 6FXR agonist models ranked by EF
calculations using the ChEMBL DB were successfully applied to
identify novel active compounds (19 and 20) from the NCI data-
base. By the application of a promoter–reporter study and analysis
of the mRNA levels of the FXR-regulated gene CYP7A1, the observed
FXR agonistic activity was conﬁrmed.
4. Experimental
4.1. Preparation of the ChEMBL database
The ChEMBL database was downloaded from the ChEMBL
Group homepage (www.ebi.ac.uk/chembldb/) and imported into
a MySQL (Sun Microsystems GmbH, Kirchheim-Heimstetten, Ger-
many) database. A MySQL query for all compounds comprising
canonical smiles, names, literature, target annotation, and pub-
lished binding afﬁnity (Ki) or biological activity (IC50/EC50) data re-
sulted in a tab-delimited ﬁle containing 1,057,661 single entries.
Subsequently, a PipelinePilot (www.accelrys.com) script was ap-
plied to divide the data by biological target and to generate 3D
structures for the compounds.
This PipelinePilot script consisted of two subprotocols. The ﬁrst
subprotocol was responsible for splitting the ChEMBL data by theiron to the original ligand, compound 11 (white), 19 established additional hydrogen
acceptor (red arrow) with His294 was observed in both compounds 11 and 19,
hree hydrophobic interactions (yellow spheres) were predicted to be identical for
tions with the receptor and could therefore be regarded as a solubility-enhancing
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and a ﬁlter component. This ﬁlter subprotocol retrieved only com-
pound data annotated with the ﬁrst target of the list and stored
these data into a tab-delimited ﬁle. Subsequently, a loop caused
the repetition of the whole subprotocol code using the next target
on the list as ﬁlter query. After the loop was executed for all tar-
gets, the resulting tab-delimited ﬁles served as input for the second
subprotocol which translated the canonical smiles code for each
compound from each target ﬁle into a 3D structure, chemically
standardized the molecules, generated all possible stereoisomers
and tautomers, calculated the protonation state at physiological
pH, energetically minimized the molecules using the Clean force
ﬁeld, and stored the results as MDL SD-ﬁle. Also this subprotocol
included a loop which caused the repeatedly execution of the code
until all tab-delimited ﬁles were converted into SD-ﬁles containing
3D structures, names, literature, and activity data for all com-
pounds for each target. This automated procedure resulted in
3485 SD-ﬁles with unique target annotation. On the one hand,
these subsets are readily available for molecular modeling experi-
ments. On the other hand, the whole ChEMBL database may be
useful to determine retrieval rates and EFs of virtual screening
experiments. For this purpose, the ChEMBL including all 302,924
unique compounds was converted into a searchable 3D multicon-
formational database using DiscoveryStudio 2.5 (www.accel-
rys.com). The Build 3D Database protocol was employed for
these calculations (FAST conformer generation algorithm with a
maximum of 250 conformers per molecule and a maximal energy
range of 20 kcal/mol above the calculated energy minimum).
4.2. Preparation of the DrugBank database
The DrugBank small molecules subset was downloaded from
www.drugbank.ca/downloads and submitted to conformational
analysis using DiscoveryStudio 2.5, using the Build 3D Database
protocol with identical settings as described for the ChEMBL
database.
4.3. Preparation of the FXR-actives dataset
The set of active FXR ligands was extracted from the ChEMBL
database (www.ebi.ac.uk/chembldb/). Out of 326 compounds that
were included in the ChEMBL subset linked with FXR activity, only
ligands with a reported EC50 <100 lM were kept. After removing
duplicate structures (among them, for example, the endogenous li-
gand CDCA) and calculating standard 3D structures using Omega2
(www.openeye.com), 221 entries remained in the FXR-actives data
set. For the modeling studies, these compounds were submitted to
conformational model analysis using DiscoveryStudio’s FAST con-
former generation algorithm employing the settings described for
the ChEMBL.
4.4. Preparation of the FXR-decoys database
The FXR decoys were extracted from the ChEMBL version 09.
Only compounds with indicated bioactivities (IC50, EC50, Ki) were
kept. From the over 390,000 remaining entries, those with similar
physicochemical properties compared to the FXR-active dataset
were kept. All decoys fulﬁlled the following criteria in comparison
to one of the FXR-active molecules: molecular weight ±50, c logP
±0.1, equal number of aromatic rings, hydrogen bond acceptors,
and hydrogen bond donors. Five thousand six hundred and thir-
teen molecules passed this ﬁltering process. Conformational anal-
ysis was performed as described for the ChEMBL database. For 15
entries, the conformer generation was not successful, so the ﬁnal
FXR-decoys database comprised 5598 compounds.4.5. Preparation of the Virtural DB
A previously generated virtual database that contains 12,775
drug-like, presumably inactive decoy molecules.30 This data set –
the so-called Virtual DB – was used to assess the model’s ability
to discard inactive compounds in a database screen. For an accu-
rate comparison of screening results, the Virtual DB was re-submit-
ted to conformational analysis using the same settings as for the
ChEMBL data set.
4.6. Preparation of the NCI database
The NCI database was retrieved from the NCI download
site (dtp.nci.nih.gov/docs/3d_database/Structural_information/
structural_data.html) and converted into a 3D database using
Catalyst 4.11 software (www.accelrys.com). The 3D multiconfor-
mational database included 247.041 compounds.
4.7. Analyses of binding modes
Ligand binding modes were analyzed using LigandScout 3 soft-
ware (www.inteligand.com). LigandScout derives protein and li-
gand atom co-ordinates from the PDB and translates them into
chemical structures according to the distances and geometries of
neighboring atoms. Ligands can be aligned using either their chem-
ical properties represented by pharmacophoric features48 or so-
called reference points which reﬂect the position of the ligand in
the protein context. The latter alignment option was used in this
study for the binding mode analysis of FXR ligands.
4.8. Pharmacophore model generation and theoretical
validation
Structure-based pharmacophore models were generated with-
in LigandScout (www.inteligand.com). This program automati-
cally analyzes interactions between the ligand and the protein
by evaluating the electrostatic and geometric (distances, size,
and angles) properties of areas where binding takes place. As a
result, the user is provided with an interaction network that
can consist of hydrophobic areas, H-bond acceptors/donors, posi-
tively or negatively ionizable/charged groups, and aromatic rings
involved in aromatic interactions. The generated models can be
used to align small sets of molecules to the model or be exported
in ﬁle formats compatible with other molecular modeling soft-
ware such as DiscoveryStudio (www.accelrys.com), MOE (www.
chemcomp.com), or Phase (www.schrodinger.com). In this study,
the model was adapted to DiscoveryStudio’s requirements – only
one H-bonding or charged feature per ligand atom – and exported
in hypoedit format. Using the hypoedit tool that comes with Dis-
coveryStudio, the model was transformed into a chm pharmaco-
phore ﬁle. The resulting model was checked for validity via
mapping of the bioactive ligand conformation it was derived
from. This step is crucial because different virtual screening pro-
grams do not use identical chemical feature deﬁnitions, which
can inﬂuence the mapping of a compound. In addition, active
FXR ligands from the FXR-actives dataset were ﬁtted into the
model. In order to create sufﬁciently representative models, they
were optimized to ﬁnd a set of active compounds while keeping
the number of decoys in the hitlist low. As a quantitative measure
of model quality, EFs were calculated using the FXR-actives and
VirtualDB, DrugBank, and ChEMBL data sets. The EF is calculated
using the equation49:
EF ¼ TP=n
A=N
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FXR-actives), n is the number of hits from virtual screening of both
the active and decoy data sets (hits FXR-actives and Virtual DB/
DrugBank/ChEMBL), A is the number of active ligands in the valida-
tion database (FXR-actives, n = 221), and N is the number of all
compounds in the validation database (221 FXR-actives plus
12,775 in the Virtual DB gives 12,996; 221 plus 4722 from the
DrugBank gives 4943, and the ChEMBL database consists of
304,273 entries that already include the FXR-actives). Database
screening for EF calculations were performed within DiscoveryStu-
dio 2.5 using the Search 3D Database protocol. Default settings
were used except for the minimum interfeature distance, which
was set to 0.00001.
The FXR ligand structures from recent literature42,43 were cre-
ated using ChemBioDraw Ultra 11.0 (www.cambridgesoft.com)
and converted into 3D multiconformational SD ﬁles using the FAST
conformer generation algorithm of DiscoveryStudio 2.5. The
calculation settings were equal to the database calculation settings
described above for the ChEMBL database.
4.9. Biological evaluation of virtual hits
4.9.1. Cell culture, plasmids, and reagents
Human embryonic kidney-293 cells (HEK-293) from American
Type Culture Collection (Manassas, VA, USA) were grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) (Sigma, St. Louis,
MO) supplemented with 10% fetal bovine serum (FBS), 1% penicil-
lin/streptomycin, 1% L-glutamine. The luciferase reporter plasmid
(ECRE)5TK-Luc, the expression vector for mouse FXR, the expres-
sion vector for mouse RXR were kindly provided by Professor Glass
CK (UCSD, La Jolla, CA). The vector pSV40-renillaLuc was obtained
from Promega (Madison, WI, USA), the pcDNA3.1 from Invitrogen
(Carlsbad, CA, USA). DMSO and 2 were purchased from Sigma–Al-
drich (St. Louis, MO).
4.9.2. Reporter gene assay
Activation of FXR was tested in HEK-293 cells seeded in 48
well plates (NUNC) and transiently transfected with the indicated
plasmids (total DNA 0.3 ng/well). Transient transfections were
performed with the calcium phosphate technique as described.50
For monitoring transfection efﬁciency pSV40-renillaLuc was
cotransfected. To normalize the amount of DNA transfected,
pcDNA3.1 vector was added where appropriate. Cells were stimu-
lated for 18 h with vehicle (DMSO) or with ligands at 25 lM
concentration.
Luciferase activity was determined from the cell lysates using
Dual-Luciferase Kit (Promega, Madison, WI, USA), measured with
Victor2 multilabel counter (Wallac, Finland). The ﬁreﬂy luciferase
values were normalized with the renilla luciferase value measured
for the respective sample (relative luciferase units). FXR induction
is expressed as fold difference of relative luciferase units (RLU)
comparing values of stimulated samples with the vehicle treated
control (mean values ± SEM) of triplicate determinations from at
least three independent experiments. Statistical signiﬁcance of
FXR induction was assessed by ANOVA-multiple comparison with
Bonferroni post-test, whereby P values of less than 0.05 were re-
garded as statistically signiﬁcant. The EC50 values were estimated
by nonlinear regression analysis using the equation for the sigmoi-
dal dose response of GraphPad Prism 4.0 (GraphPad Software Inc.,
La Jolla, CA).
4.9.3. Analysis of expression of FXR downstream genes by qPCR
HepG2 cells were grown in 24-well dishes (NUNC) in DMEM
supplemented with antibiotics (100 U/ml penicillin, 100 lg/ml
streptomycin, 25 lg/ml amphotericin B), 1% glutamine and 10%
FBS. The cells were stimulated in the same medium with the ana-lyzed compounds or positive control (2) dissolved in DMSO (ﬁnal
concentration 0.1%) at a concentration of 50 lM for 6 h. The incu-
bation was terminated and RNA was isolated using TriFast reagent
(PeqLab, Erlangen, Germany). A GeneAmp RNA-PCR kit and oligo
d(T)16 primers (Applied Biosystems, Foster City, CA) were used
for cDNA synthesis from 900 ng of total RNA. Quantitative real-
time PCR (qPCR) was performed using the Step One Plus (Applied
Biosystems), FastStart SYBR Green Master Mix (Roche Diagnostics,
Indianapolis, IN), and speciﬁc primers for ampliﬁcation of CYP7A1
(Qiagen, Venlo, The Netherlands). CYP7A1 expression was normal-
ized to the expression levels of 2-microglobulin using primers ob-
tained from the same company.
4.10. Novelty assessment of compound 19
Apart from literature search using SciFinder and investigation of
the data provided by the NCI, compound 19was topologically com-
pared with bioactive compounds reported in the WOMBAT and
MDDR database. For this experiment, the sea.docking.org45 online
portal was used. Scitegic’s ECFP4 ﬁngerprinting algorithm was
used for identifying compounds that are structurally related to
compound 19. The search returned targets on which related com-
pounds have reported to be active and ranked them according to
the signiﬁcance of the resulting similarity scores. From the results,
compound 19 has not been associated with FXR before.
4.11. Identity and purity determination
Compounds 19 and 20 fulﬁlled the identity and purity criteria
(P95%) as determined by HPLC.
4.12. Mapping of compound 19 into the FXR binding site
The 1osh-1-s model-mapping conformation of compound 19
was copied into the X-ray crystal structure co-ordinates of FXR
(PDB entry 1osh). In order to optimize the ﬁtting of the compound
into the binding site, it was minimized using the MMFF94 force
ﬁeld implemented in LigandScout 3.02. Protein–ligand interactions
were automatically analyzed using LigandScout and visually
inspected.
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